Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1684/ejd.2013.2068 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors influencing therapeutic efficacy of denosumab against osteoporosis in systemic lupus erythematosus.
Lupus Sci Med
January 2025
Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Objective: Osteoporosis is a common comorbidity in patients with SLE, and bone loss in patients with SLE has a multifactorial aetiology. This study aimed to evaluate the therapeutic efficacy of denosumab in patients with SLE with osteoporosis and to analyse the factors influencing therapeutic efficacy.
Methods: A total of 166 patients with SLE with osteoporosis who initiated denosumab between January 2016 and December 2023 were included.
Occurrence and molecular identification of haemotropic Mycoplasma species in grey wolves (Canis lupus) from southern Europe.
Vet Microbiol
January 2025
Departamento de Sanidad Animal, Grupo de Investigación en Sanidad Animal y Zoonosis (GISAZ), UIC Zoonosis y Enfermedades Emergentes ENZOEM, Universidad de Córdoba, 14014 Córdoba, Spain; CIBERINFEC, ISCIII CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Although wild and domestic carnivores share some haemotropic Mycoplasma species, information about the circulation of this pathogen in grey wolves (Canis lupus) populations is still very limited. Thus, a geographically broad-based investigation was performed for determining the occurrence and diversity of Mycoplasma spp. in three different wolf populations from southern Europe.
View Article and Find Full Text PDFIntroduction: Thrombotic microangiopathies (TMA) represent distinct pathological and clinical entities with known chronicity and recurrence. Kidney biopsy is the gold standard to diagnose TMA in patients with renal manifestations but the prognostic significance of acute or chronic phase of the disease has not been well studied. We examined the clinical characteristics, management, and predictors of acute vs.
View Article and Find Full Text PDFExploring Patient Activation and Compliance in Patients with Different Rheumatological Disorders.
Healthcare (Basel)
January 2025
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
This study aimed to assess patient activation using patient activation measure 13 (PAM-13) in systemic lupus erythematosus (SLE), psoriatic arthritis (PsA), and axial spondyloarthritis (axSPA). A cross-sectional study was conducted involving patients with three rheumatological conditions (SLE, PsA, and axSPA). Patients were contacted either at the clinic or through social media platforms.
View Article and Find Full Text PDFHealthcare costs of systemic lupus erythematosus in New Zealand.
Lupus
January 2025
Medical Research Centre, The University of Waikato, Hamilton, New Zealand.
Objectives: This study aims to estimate the annual medical costs of systemic lupus erythematosus (SLE) in New Zealand (NZ).
Methods: SLE patients were linked to the Australia and New Zealand Dialysis and Transplant Registry, Pharmaceutical Collection, National Minimum Dataset, National Non-Admitted Patients Collection and Mortality Collection. National direct medical costs of SLE in 2006-2021 and annual costs per patient were estimated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!